Treatment of Pediatric Ocular Melanoma With High-Dose Interleukin-2 and Thalidomide

Soni, Sandeep; Lee, David S.; DiVito, Joseph; Bui, Au H.; DeRaffele, Gail; Radel, Eva; Kaufman, Howard L.

doi:10.1097/00043426-200208000-00016

Cited by 28 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BT does, however, provide excellent tumor control, with local control rates exceeding 90% 41. A single-center study of 458 patients with predominantly medium-sized choroidal melanomas treated with 108Ru brachytherapy reported actuarial rates of tumor recurrence to be 1%, 2%, and 3% at 2, 5, and 7 years, respectively 42. Visual outcomes are dependent upon tumor location and thickness, with one large study reporting an actuarial rate of 55% for conservation of vision 20/40 or better at 9 years 43.…”

Section: Treatment Of the Primary Tumormentioning

confidence: 99%

See 1 more Smart Citation

Current and emerging treatment options for uveal melanoma

Pereira¹,

Odashiro²,

Lim³

et al. 2013

OPTH

View full text Add to dashboard Cite

Uveal melanoma (UM) is the most common primary malignant intraocular tumor in adults, with a 10-year cumulative metastatic rate of 34%. The most common site of metastasis is the liver (95%). Unfortunately, the current treatment of metastatic UM is limited by the lack of effective systemic therapy. Options for the management of the primary intraocular tumor include radical surgery as well as conservative treatments in order to preserve visual acuity. For metastatic disease, several approaches have been described with no standard method. Nevertheless, median survival after liver metastasis is poor, being around 4–6 months, with a 1-year survival of 10%–15%. In this review, the authors summarize current and promising new treatments for UM.

show abstract

Section: Treatment Of the Primary Tumormentioning

confidence: 99%

“…However, no clinical trials of IL-2 in metastatic UM have been performed. Soni et al108 reported an 8-year-old girl with UM metastatic to liver and pancreas who was treated with highdose bolus IL-2 and thalidomide. The patient experienced minimal toxicity and had stable disease for 23 months.…”

Section: Systemic Therapiesmentioning

confidence: 99%

Current and emerging treatment options for uveal melanoma

Pereira¹,

Odashiro²,

Lim³

et al. 2013

OPTH

View full text Add to dashboard Cite

show abstract

“…Many of the reports of side effects associated with BRM administration have been single case studies [15][16][17][18], used retrospective or cross-sectional designs [19], or used lower dosages of BRMs than is usually used to treat melanoma [20]. None have measured HRQOL associated with high-dose IFN administration in melanoma patients prospectively during Having accurate information on the QOL and toxicities associated with administration of BRMs is important for consideration of these therapies for the future.…”

Section: Introductionmentioning

confidence: 99%

Validation of the FACT-BRM with interferon-α treated melanoma patients

Paterson¹,

Trask²,

Wagner

et al. 2005

Qual Life Res

View full text Add to dashboard Cite

The somatic, neurocognitive, and psychiatric side effects of biological response modifiers (BRMs) have been documented in specific patient samples. Although these side effects likely have a predictable impact on patients quality of life (QOL), no instrument currently measures the cumulative effect of the various complaints patients' report. The current study investigated the reliability and validity of the Functional Assessment of Cancer Treatment-Biological Response Modifier (FACT-BRM) scale for measuring QOL in a sample of melanoma patients receiving interferon. Measures of distress, depression, and fatigue were also obtained using standardized, well-validated instruments. Results indicate increased symptom burden, depression, and fatigue, and decreased quality of life over 4 months of IFN therapy. The FACT-BRM demonstrated good psychometrics and sensitivity to change, and thus appears to be a good instrument for measuring QOL in patients receiving BRMs.

show abstract

“…Case reports suggested that interleukin-2 administered together with other immune response modifiers might be effective in choroidal melanomas. 54,55 Soni et al reported on an 8-year-old girl with metastatic uveal melanoma who was treated with high-dose bolus IL-2 plus thalidomide that resulted in regression of liver, pancreatic, and pulmonary metastases with control of her disease that lasted for over 3.5 years. 54 Minor et al reported a patient with choroidal melanoma metastatic to the liver treated with interleukin-2 (IL-2), LAK, and interferon who survived over 5 years.…”

Section: Intravenous Chemotherapymentioning

confidence: 99%

“…54,55 Soni et al reported on an 8-year-old girl with metastatic uveal melanoma who was treated with high-dose bolus IL-2 plus thalidomide that resulted in regression of liver, pancreatic, and pulmonary metastases with control of her disease that lasted for over 3.5 years. 54 Minor et al reported a patient with choroidal melanoma metastatic to the liver treated with interleukin-2 (IL-2), LAK, and interferon who survived over 5 years. 55 Agarwala et al reviewed the results of treatment of 39 patients with metastatic uveal melanoma included in IL-2 plus histamine phase 2/3 clinical trials for patients with melanoma.…”

Section: Intravenous Chemotherapymentioning

confidence: 99%

Metastatic Uveal Melanoma Therapy

Bedikian¹

2006

International Ophthalmology Clinics

113

View full text Add to dashboard Cite

Uveal melanoma is the most common primary intraocular malignant tumor in adults and the second most common type of primary malignant melanoma in the body. It represents 5% to 6% of all melanoma diagnoses. Metastasis is by vascular spread, and approximately 40% to 50% of patients with primary uveal melanoma will ultimately develop metastases. At the time of diagnosis, over 99% of patients have disease limited to the eye, but at least 30% of these patients will die of systemic metastases at 5 years and 45% at 15 years. 1 Of the patients who die of uveal melanoma, 62% and 90% do so within 5 and 15 years, respectively. The liver is involved in up to 95% of individuals who develop metastatic disease. 2,3 The survival of patients with metastatic uveal melanoma is directly related to the presence of liver metastasis. Liver is the first site of systemic metastasis for most patients and the exclusive site of systemic metastasis in approximately 40% of the patients. The clinical course of patients with uveal melanoma is determined by progression of the disease in the liver. Despite therapy, the median survival of patients who develop liver metastases is reported to be about 6 months, and the 1-year survival is estimated to be 10% to 15%. 4 In contrast, patients with metastatic melanoma confined to extrahepatic sites have a median survival of approximately 19 to 28 months with 76% of the patients surviving over a year. 1,5,6 n Prognosis and Treatment of Disseminated Uveal MelanomaDespite advances in diagnosis and management of the primary uveal melanoma, systemic uveal melanoma metastases are difficult to treat. 6 The management of metastatic uveal melanoma is dependent on whether metastatic disease is confined to the liver. Regional therapies such as surgical resection, isolated hepatic perfusion, intraarterial hepatic

show abstract

Treatment of Pediatric Ocular Melanoma With High-Dose Interleukin-2 and Thalidomide

Cited by 28 publications

References 27 publications

Current and emerging treatment options for uveal melanoma

Current and emerging treatment options for uveal melanoma

Validation of the FACT-BRM with interferon-α treated melanoma patients

Metastatic Uveal Melanoma Therapy

Contact Info

Product

Resources

About